Abstract | BACKGROUND: METHODS: We prospectively enrolled 600 patients. Of these, 180 underwent E-ZES and 420 underwent EES implantation. Clinical follow-up was performed up to 7 years (median follow-up 61 months). The evaluated clinical outcomes were Target Lesion Failure (TLF), a composite of cardiac death, myocardial infarction and Target Lesion Revascularization (TLR), the Patient-Related Outcome (PRO) and stent thrombosis. Differences between groups evaluated with the Kaplan-Meier method and possible independent predictors with Cox proportional hazard regression. RESULTS: At 5 years, the cumulative probability for outcomes was: TLF: 13.8% versus 7.5%, p=0.025, cardiac death: 3.1% versus 2.5%, p=0.937, myocardial infarction: 1.2% versus 1.8%, p=0.829, TLR: 10% versus 3.3%, p=0.003, PRO: 19.6% versus 13.8%, p=0.528, ST: 2.5% versus 2.7%, p=0.965, for E-ZES and EES respectively. Differences between stents increased after 30 months. In multivariate analysis predictors of TLF adjusted for stent type were Diabetes mellitus and estimated Glomerular Filtration Rate (eGFR). CONCLUSION: Both stents provided a favorable safety profile, with EES demonstrating better effectiveness. There was a late emergence in difference of endpoints after 30 months. Diabetes mellitus and eGFR predicted TLF.
|
Authors | Konstantinos Toutouzas, Nikolaos Anousakis-Vlachochristou, Chrysoula Patsa, Ioannis L Matsoukis, Maria Drakopoulou, Eleftherios Tsiamis, George Latsios, Andreas Synetos, Evmorfia Komatanou, Anastasios Spanos, Eleni Th Petridou, Dimitris Tousoulis |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 183
Pg. 27-32
(Mar 15 2015)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 25662050
(Publication Type: Journal Article)
|
Copyright | Copyright © 2015 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Immunosuppressive Agents
- Everolimus
- zotarolimus
- Sirolimus
|
Topics |
- Aged
- Angina, Stable
(diagnosis)
- Coronary Artery Disease
(surgery)
- Drug-Eluting Stents
- Everolimus
(therapeutic use)
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Prospective Studies
- Sirolimus
(analogs & derivatives, therapeutic use)
|